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ABSTRACT: The most common cause of death in cystic fibrosis (CF) patients is
progressive lung function decline, which is punctuated by acute pulmonary exacerbations
(APEs). A major challenge is to discover biomarkers for detecting an oncoming APE and
allow for pre-emptive clinical interventions. Metabolic profiling of exhaled breath
condensate (EBC) samples collected from CF patients before, during, and after APEs
and under stable conditions (n = 210) was performed using ultraperformance liquid
chromatography (UPLC) coupled to Orbitrap mass spectrometry (MS). Negative ion
mode MS data showed that classification between metabolic profiles from “pre-APE”
(pending APE before the CF patient had any signs of illness) and stable CF samples was
possible with good sensitivities (85.7 and 89.5%), specificities (88.4 and 84.1%), and accuracies (87.7 and 85.7%) for pediatric
and adult patients, respectively. Improved classification performance was achieved by combining positive with negative ion
mode data. Discriminant metabolites included two potential biomarkers identified in a previous pilot study: lactic acid and 4-
hydroxycyclohexylcarboxylic acid. Some of the discriminant metabolites had microbial origins, indicating a possible role of
bacterial metabolism in APE progression. The results show promise for detecting an oncoming APE using EBC metabolites,
thus permitting early intervention to abort such an event.
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■ INTRODUCTION
In cystic fibrosis (CF), the frequency and severity of acute
pulmonary exacerbations (APEs) are important determinants
for accelerated lung function decline and increased mortality.1,2
The CF Foundation Patient Registry shows that 24% of
children with CF and 43% of adults with CF had one or more
APEs that required intravenous antibiotics treatment in 2017.3
There are no consensus diagnostic criteria for CF APEs, as
most of the current criteria are based on empirical data that has
not been formally validated and may thus cause problematic
treatment decisions.4 In addition, there is no pre-emptive
screening method for stable CF patients to signal an oncoming
APE, which hinders the implementation of an early
intervention.5 These drawbacks emphasize the need for better
biomarkers to improve APE diagnosis and to predict oncoming
APE events.
Biomarkers indicating on-going CF APEs have been
proposed for various types of biofluids. Only a few, however,
have been demonstrated to be predictive of exacerbation. The
most extensively studied blood biomarker is the C-reactive
protein, which was found to correlate with CF disease severity
with a significant increase in APEs compared to baseline in
stable CF patients and a significant decrease after treatment.6
Compared to proteins, metabolites are closer in proximity to
the phenotype and their changes can better reflect the status of
a biological system.7 Several metabolomics studies have
revealed detectable metabolic alterations associated with CF
APEs. In a plasma metabolomics study by Laguna et al., for
example, metabolic profiles of matched paired samples from 25
CF patients collected during an APE and during outpatient
clinic visits were analyzed by liquid chromatography (LC)
mass spectrometry (MS) and gas chromatography−MS.8 Five
out of 398 identified metabolites showed significant alterations
between stable CF patients and patients undergoing an APE,
including hypoxanthine, N4-acetylcytidine, N-acetylmethio-
nine, mannose, and cortisol.8 Quinn et al. identified the
platelet activating factor and related lipids as potential
biomarkers for CF APEs in sputum from 11 CF patients,
with the advantage that this biofluid is less invasive to collect
than blood.9 However, most young children and many CF
teens do not expectorate sputum when clinically stable. Thus,
the use of sputum targets those adult patients with established
airway disease and holds less promise for detecting disease in
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pediatric patients. Exhaled breath condensate (EBC) is another
biofluid that can be analyzed to establish differences prior to
and during an APE, with the advantage that it can be easily
collected from patients of all ages, including small children and
with a wide variety of airway disease severity, including those
with mild disease and little sputum production.10 Despite this
potential usefulness, only one study11 has investigated the
discrimination of stable CF patients (n = 29) from CF patients
during exacerbations (n = 24). By using nuclear magnetic
resonance (NMR) spectroscopy, ethanol, acetic acid, 2-
propanol, and methanol were identified as discriminating
EBC metabolites.11 Together with our prior pilot study of 35
CF subjects where we identified metabolites present in EBC
several weeks before an APE became clinically apparent,12
these investigations suggest that EBC metabolomics has the
potential of revealing the biological pathways altered in the
development and progression of an APE in CF, prompting the
examination of a larger and better controlled patient cohort.
We here present an EBC metabolomics study of a patient
cohort that included 97 stable CF patients, 36 pre-APE
patients, 41 APE patients and 36 post-APE patients, with two
aims: (a) to compare the results with those from our pilot
study and (b) to identify more robust EBC biomarkers for CF
APE prediction and detection in adult and pediatric patients.
■ MATERIALS AND METHODS
Details on chemical reagents, EBC sample collection, and
preparation for analysis, instrumental settings for metabolic
profiling, metabolite identification by ion mobility (IM), and
detailed data analysis procedures are provided in the
Supporting Information section. All datasets are shared in
t h e Me t a bo l om i c s Wo r kb en ch (h t t p s : / /www .
metabolomicsworkbench.org/) with doi: 10.21228/M8409J.
Cohort Description
CF patients were seen in the clinic every three months when
stable and more frequently with exacerbations. EBC was
collected during these regular clinic visits to the Emory +
Children’s CF Care Center in Atlanta, Georgia, after obtaining
informed consent. The patient’s clinical course was then
followed over the subsequent months so that they could be
grouped according to their APE status. Clinically stable CF was
defined as CF subjects whose symptoms were at the baseline,
physical examination of the lungs was at the baseline, percent
predicted forced expiratory volume in 1 s (ppFEV1) was within
10% of the yearly baseline, and no new therapies (particularly
antibiotics) were added at that clinic visit; the patient was seen
at the next clinic visit three months later and was again
classified as clinically stable. EBC that was collected at the first
of these paired clinically stable clinic visits was used for
metabolic profiling of the clinically stable patient cohort as
there was no APE identified in the three months following
EBC collection. Ninety-seven CF subjects (age range 5−66,
50% female) met this definition of clinically stable without an
APE in the subsequent 3 months. A severe APE was defined as
an increase in respiratory symptoms (cough and sputum
production) and/or changes in physical examination of the
lungs (increase in crackles and decrease in airflow), at least a
10% decrease in baseline ppFEV1, and (in the opinion of the
clinician) requiring hospitalization for treatment of the APE. In
many instances, this was because outpatient treatment failed to
restore the patient to baseline. Thus, use of the criteria that
ppFEV1 was decreased by at least 10% of baseline and that
hospitalization was required resulted in the study of more
severe APEs that did not respond to outpatient treatment.
EBC was collected in 41 of such subjects with a severe APE at
the time of hospitalization (age range 8−58, 56% female). In
36 subjects, EBC was collected 1−3 months after an APE
event requiring hospitalization, labeled as post-APE (age range
8−64, 64% female). Finally, EBC was collected in 36 subjects
who were clinically stable as defined above but in the
subsequent 1−3 months developed APEs severe enough to
require hospitalization, labeled as pre-APE (age range 8−61,
61% female). Because of the wide age distribution in the
patient cohort, samples were separated into adult (age > 18)
and pediatric (age ≤ 18) groups within each class. Attempts to
classify samples by type of bacterial infection (e.g.,
Pseudomonas vs MSSA vs MRSA) or CF-related diabetes
status did not produce any obvious subgroups and were not
further pursued. Sample data from patients of pediatric and
adult groups were preprocessed and filtered, and these features
were analyzed by principal component analysis (PCA); outliers
outside 95% confidence intervals were removed. Subsequently,
orthogonal partial least-squares-discriminant-analysis (oPLS-
DA) binary classification models were performed for age- and
gender-matched samples in each group (Table S1). For stable
CF versus pre-APE comparisons, there were 3 pediatric and 9
adult patients that provided both a stable CF and a pre-APE
sample. For the stable CF versus APE comparison, there were
4 pediatric and 2 adult patients providing both a stable CF and
an APE sample.
Metabolic Profiling by Ultraperformance Liquid
Chromatography−MS
Ultraperformance liquid chromatography (UPLC)−MS meta-
bolic profiling analyses were performed on a Dionex Ultimate
3000 system (Thermo Scientific, Dionex, Sunnyvale, Cal-
ifornia, USA) equipped with a Waters ACQUITY UPLC BEH
C18 column (2.1 × 50 mm, 1.7 μm particle size, Waters
Corporation, Milford, MA, USA), coupled to a Thermo
Scientific Q Exactive HF hybrid quadruple−Orbitrap mass
spectrometer. The main mass spectrometer parameters were as
follows: capillary voltage 3.1 kV, capillary temperature 300 °C,
S-lens RF 50.0%, sheath gas, auxiliary gas and sweep gas flow
rate 48, 11, and 2 arbitrary units, respectively, and auxiliary gas
heater temperature 413 °C. The m/z scan range was 50.0−
750.0 with an automatic gain control (AGC) target of 3 × 106
and maximum injection time of 512 ms. The mass resolution
setting was 240 000. For UPLC−MS/MS experiments, the
product ion-mass spectra were acquired with a resolution of
30 000, AGC target of 1 × 105, maximum injection time of 64
ms, isolation window of 0.4 m/z and normalized collision cell
voltages between 10 and 100 V, depending on the analyte.
Additional details are provided in the Supporting Information
section.
Metabolite Identification and Pathway Analysis
Spectral features with tentative candidates in the Human
Metabolome Database (HMDB)13 were targeted for further
identification based on (i) their accurate mass and isotopic
pattern, (ii) tandem MS experiments, where the respective
precursor ions were quadrupole-selected and -activated, and
search of MS/MS spectra in the Metlin database,14 and (iii)
further validation against chemical standards (when available).
For those cases in which MS/MS spectra were not available in
the Metlin database for comparison, fragmentation patterns
were manually interpreted for metabolite annotation. Com-
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mercially available standards were analyzed under identical
conditions as EBC samples to validate putative metabolite
identities by chromatographic retention time (Rt) matching
and MS/MS fragmentation pattern matching. For metabolites
with Rt at the solvent front, collision cross-section (CCS)
values were measured using IM MS to provide an additional
molecular descriptor to increase identification confidence by
comparing to those of chemical standards (see the Supporting
Information section). Pathway analysis was performed with
Metaboanalyst v3.0.15 A total of 23 uniquely identified
discriminant metabolites from all panels (metabolites in Tables
S3 and S4) were chosen for analysis. Data were autoscaled, and
other parameters were kept with default settings.
■ RESULTS AND DISCUSSION
Data Extraction Results
A total of 1334 and 923 features were obtained from UPLC−
MS data in negative and positive ion modes, respectively.
Adducts, in-source fragment ions, and chloride salt cluster ions
were grouped according to criteria in Table S2. The quality
control sample-based robust locally estimated scatterplot
smoothing (LOESS) signal correction (QC-RLSC) was
applied to the data, followed by removal of features with
relative standard deviation > 30% in quality control (QC)
samples.16 After blank correction, features with zero values in
>80% of samples considering all classes (stable CF, pre-APE,
APE, and post-APE) were removed, leaving 1015 and 635
features in negative and positive ion mode data, respectively.
Subsequently, contaminants and electrospray ionization (ESI)
artifacts such as chloride salt cluster ions and high mass defect
ions defined by the McMillan filter17 were removed, leaving
745 and 538 features in negative and positive ion mode data,
respectively. The resulting data matrices were normalized by
total ion intensity and then passed through a 50% sample
prevalence filter that preserved features present in ≥50%
samples within one of the sample groups used for binary
classification, yielding 281 and 262 features in negative and
positive ion mode data for APE/stable CF classes, and 278 and
268 features in negative and positive ion mode data for pre-
APE/stable CF classes. The remaining features were then
searched in the HMDB and only those with endogenous
human or microbial candidate identities were retained. This
putative identity filter was performed to ensure the features
used for multivariate analysis had a high chance of being
identified as human endogenous or microbial compounds and
minimize false positive identifications. One limitation of this
approach, however, is that it sacrifices the chances of
discovering potentially novel discriminant compounds. Follow-
ing this step, 58 and 46 features remained in negative and
positive ion mode data for the APE/stable CF class pair, and
57 and 44 compounds for the pre-APE/stable CF class pair.
These remaining features constituted the final datasets used for
subsequent multivariate analyses. EBC metabolome finger-
prints are illustrated in heat maps (Figure S1) for visualization
of differences among features across all sample classes from
pediatric and adult patients. In the pediatric group, APE
metabolic profiles showed differences from the other three
groups, with more compounds increasing in relative
abundance; in the adult group, metabolic profiles for APE
EBC samples were similar to those of post-APE samples. For
both pediatric and adult groups, the distinction between pre-
APE and stable CF metabolic profiles was not obvious in the
heat maps. PCA was performed for each age group with the
final set of features after data preprocessing and filtering steps,
and outliers outside 95% confidence intervals were removed.
For combined negative and positive mode data, there were 1
adult pre-APE outlier, and 1 pediatric and 4 adult stable CF
outliers for the pre-APE versus stable CF comparison, and 3
pediatric and 3 adult APE outliers and 4 adult stable CF
Figure 1. oPLS-DA cross-validated classification plots using negative ion mode data, including comparison of APE vs stable CF samples in age- and
gender-matched EBC samples from pediatric patients (A) and those from adult patients (B), and comparison of pre-APE vs stable CF samples in
age- and gender-matched EBC samples from pediatric patients (C) and those from adult patients (D). The x-axis represents the sample number,
and y-axis represents the cross-validated predicted scores of the oPLS-DA classification model. APE/pre-APE and stable CF samples are
represented by red circles and black squares, respectively. The decision threshold is represented as a green dashed line.
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outliers for the APE versus stable CF comparison. Then,
interval PLS-DA (iPLS-DA) feature selection and oPLS-DA
binary classification models were built for age- and gender-
matched samples in each age-based group (Table S1).
Classification Performance
Data analysis of negative ion mode data showed that
discrimination of APE from stable CF samples was possible
in both adult and pediatric groups (Figure 1 and Table S3).
For classification of pediatric patients, nine discriminant
features were selected by iPLS-DA, yielding a sensitivity of
83.3%, specificity of 91.7%, and accuracy of 88.9%. For the
adult group, the oPLS-DA model provided a sensitivity of
76.2%, specificity of 83.7%, and accuracy of 81.3% in
distinguishing 21 APE samples from 43 stable CF samples,
using a panel of 10 discriminant features with six latent
variables. For discrimination of pre-APE samples from stable
Table 1. Identification of Discriminant Features in oPLS-DA Classification of APE Samples from Stable CF Samples Using










(APE/stable CF) identification method
pediatric 89.0232 0.55 [M − H]− lactic acid C3H6O3 2.5 CCSa and MS/MSa,b
128.0342 0.53 [M − H]− pyroglutamic acid C5H7NO3 1.5 CCSa and MS/MSa,b
127.0503 0.87 [M − H]− dihydrothymine C5H8N2O2 3.0 MS/MSc
59.0125 0.56 [M − H]− acetic acid C2H4O2 −1.7 CCSa
130.0499 0.57 [M − H]− C5H9NO3 1.6 d
143.0340 0.58 [M − H]− 3-methylglutaconic acid,
2-methylglutaconic acid, 2-hexenedioic
acid, 3-hexenedioic acid
C6H8O4 −1.4 MS/MSc for 2-hexenedioic
acid, MS/MSa for the other
candidates
227.1036 0.66 [M − H]− prolylhydroxyproline C10H16N2O4 1.8 MS/MSc
165.0549 1.77 [M − H]− C9H10O3 2.4 d
187.0064 0.64 [M − H]− C7H8O4S N/Ae d
adult 143.0704 0.67 [M − H]− 4-hydroxycyclohexylcarboxylic acid C7H12O3 1.5 CCSa and MS/MSa,c
187.0970 0.63 [M − H]− nonanedioic acid, azelaic acid C9H16O4 2.5 CCSa and MS/MSa,b
201.1128 1.07 [M − H]− sebacic acid C10H18O4 1.6 Rta and MS/MSa,b
85.0283 0.61 [M − H]− γ-butyrolactone, oxolan-3-one C4H6O2 1.6 MS/MSc
115.0389 0.59 [M − H]− levulinic acid C5H8O3 N/A MS/MSa,c
157.0862 0.97 [M − H]− 4-hydroxycyclohexylacetic acid C8H14O3 1.5 MS/MSc
59.0125 0.56 [M − H]− acetic acid C2H4O2 −1.4 CCSa
165.0549 1.77 [M − H]− C9H10O3 3.3 d
168.0658 0.73 [M − H]− C8H11NO3 −1.3 d
177.0397 0.53 [M − H]− C6H10O6 1.6 d
aMatch to chemical standard. bMatch to Metlin MS/MS. cMatch to manual analysis. dNo endogenous ID, not match to chemical standard, match
to Metlin MS/MS or match to manual analysis. eUnable to calculate median fold change because the denominator is 0.
Table 2. Identification of Discriminant Features in oPLS-DA Classification of Pre-APE Samples from Stable CF Samples Using








(pre-APE/stable CF) identification method
pediatric 89.0232 0.55 [M − H]− lactic acid C3H6O3 1.3 CCSa and MS/MSa,b
133.0132 0.86 [M − H]− malic acid C4H6O5 −2.0 × 102 Rta and MS/MSa,b
189.0762 0.59 [M − H]− 3-hydroxysuberic acid C8H14O5 1.4 MS/MSc
329.2338 6.73 [M − H]− 9,10,13-TriHOME C18H34O5 1.3 MS/MSc
73.0277 0.64 [M − H]− propionic acid C3H6O2 −1.1 CCSa and MS/MSa,c
130.0499 0.57 [M − H]− C5H9NO3 1.9 d
145.0973 0.70 [M − H]− lysine C6H14N2O2 2.9 Rta and MS/MSa,b for
positive mode
101.0596 0.80 [M − H]− C5H10O2 N/Ae d
122.0237 1.40 [M − H]− C6H5NO2 N/A d
187.0064 0.64 [M − H]− C7H8O4S N/A d
213.1493 5.97 [M − H]− C12H22O3 1.6 d
adult 143.0704 0.67 [M − H]− 4-hydroxycyclohexylcarboxylic acid C7H12O3 1.8 CCSa and MS/MSa,c
137.0234 0.74 [M − H]− salicylic acid C7H6O3 2.5 Rta and MS/MSa,b
157.0862 0.97 [M − H]− 4-hydroxycyclohexylacetic acid C8H14O3 2.1 MS/MSc




130.0499 0.57 [M − H]− C5H9NO3 1.0 d
aMatch to chemical standard. bMatch to Metlin MS/MS. cMatch to manual analysis. dNo endogenous ID, not match to chemical standard, match
to Metlin MS/MS or match to manual analysis. Significant median fold change is shown in italics. eUnable to calculate median fold change because
the denominator is 0.
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CF EBC samples, another set of oPLS-DA models was built
that provided sensitivities of 85.7 and 89.5%, specificities of
88.4 and 84.1%, and accuracies of 87.7 and 85.7% for
differentiating samples of 14 pre-APE pediatric patients or 19
adult patients from 43 stable pediatric patients or 44 adult
patients, respectively. All models had good area under the
receiver operating characteristic curve (AUC) values ranging
from 0.8 to 0.9, with permutation testing showing no
overfitting.
Data analysis was also performed on the dataset combining
positive and negative ion mode spectral features. Results
showed classification was also feasible when samples were
separated into adult and pediatric groups and improved
classification performance was obtained for most comparisons
with accuracies enhanced between 3 and 9.3% (Table S4 and
Figure S2). All models had high AUC values of approximately
0.9, and no indication of overfitting as suggested by
permutation test results.
It is worth mentioning that attempts were initially performed
to discriminate between pre-APE and stable CF patients
without splitting the cohort into adult and pediatric subgroups,
but results were not satisfactory. For example, using the
combined negative and positive mode LC−MS data, the
sensitivity and specificity obtained from the oPLS-DA
classification model for the pre-APE versus stable CF binary
comparison were lower (74.3 and 88.0%, respectively, Figure
S3) than those obtained when separated pediatric (100 and
87.5%) and adult (85.7 and 97.7%) patient cohorts were
analyzed (Table S4). In addition, when lactic acid abundance
was plotted against patient age for pre-APE and stable CF
samples, different levels were observed for pediatric and adult
patients (Figure S4). Overall, the average lactic acid level in
pediatric patients was significantly higher than that in adult
patients (p = 1.3 × 10−5). Based on these results, samples were
grouped into adult and pediatric groups for classification with a
cut-off age of 18 years of age.
Identification of Discriminant Metabolites and Their
Biological Relevance
Experimental MS/MS spectra of discriminant features were
matched to entries in the Metlin database or manually analyzed
if no database spectra were available. In addition, if a chemical
standard was available, both retention time (Rt) and MS/MS
spectrum of the discriminant feature were compared to it.
Because some features co-eluted with the chromatographic
solvent front (Rt = 0.5−0.7 min), CCS was used as an
additional molecular descriptor for identification instead of Rt.
A more confident identity is reported if CCS values matched
with chemical standards within 2% (Tables 1 and 2 and Tables
S5 and S6). Figure S5 shows an example of a positive-ion
mode identification of a discriminant feature with m/z
175.1188 by comparison of its MS/MS spectrum to the
arginine chemical standard. In addition, Rt and CCS were also
matched (Table S6).
In this work, metabolic profiling of EBC samples was
conducted with a larger patient cohort (n = 210) than our
prior pilot study to investigate potential EBC biomarkers for
APE detection and prediction by means of a nontargeted
UPLC−MS-based method coupled to multivariate statistical
analysis. Both negative ion mode data and combined positive
and negative ion mode data showed classification of APE and
pre-APE patients from stable CF patients in both adult and
pediatric cohorts. Supervised multivariate statistical models
yielded good classification accuracies ranging between 81.3 and
93.9%, depending on the binary comparison, with AUC values
of ∼0.8−0.9, and provided different discriminant EBC
metabolite panels for APE and pre-APE detection in adult
and pediatric patients.
Of all discriminant features, some have been reported as
being connected with microbial metabolism, re-emphasizing
the important role that the CF microbiome has in terms of
interacting with the host and participating in inflammatory
mechanisms during and before the onset of an APE. Several
discriminant metabolites showed interesting trends in their
abundance changes in EBC samples from patients at different
stages preceding and following an APE event, in pediatric
cohorts, including lactic acid, leucine/isoleucine, and butyric
acid (Figure 2).
In EBC samples from pediatric patients, lactic acid was
significantly elevated in APE samples compared to stable, pre-
and post-APE ones (Figure 2A). This compound was also
selected by iPLS-DA in the model comparing EBC samples
from pre-APE patients with those from stable CF patients in
the pilot study.12 In the model comparing adult APE and stable
Figure 2. Box plots for discriminant metabolites with changing trends
in pediatric patients: (A) lactic acid, (B) leucine and/or isoleucine,
and (C) butyric acid. Mean values are represented by an open square;
median values are represented by a line in the box; the edges of the
box are 25th and 75th percentiles; the whisker extends to the most
extreme values in data not including outliers, with a 99.3% coverage;
outliers are represented by asterisks.
Journal of Proteome Research Article
DOI: 10.1021/acs.jproteome.9b00443
J. Proteome Res. 2020, 19, 144−152
148
CF samples, however, lactic acid was not included because
compared to pediatric patients, adult patients had lower
abundance of lactic acid in the APE group, and changes
between the stable CF and APE groups were not statistically
significant. Lactic acid is a fermentation metabolite of the
anaerobic microbial community in CF and a potential
biomarker associated with CF progression.18 In a sputum
metabolomics study, lactic acid was detected with significantly
increased levels in samples from APE patients compared to
those from stable CF patients using LC−MS/MS.19 The mean
abundance of leucine/isoleucine exhibited an increasing trend
in EBC samples from stable CF to pre-APE pediatric patients,
and a decreasing trend from pre-APE to APE, and from APE to
post-APE (Figure 2B). The decrease in mean abundance from
the pre-APE to the APE group in the cohort might be due to
the fact that over 50% of the APE patients had already started
intravenous antibiotic treatment at the time of EBC collection,
resulting in a different inflammatory phenotype from that in
pre-APE patients, who had not yet been aggressively treated.
Leucine was reported as an important discriminant metabolite
for classification of CF patients with high and low
inflammation.20 It should also be noted that the catabolism
of branched chain amino acids such as leucine and isoleucine is
subjected to the carbon catabolite repression control in
Pseudomonas aeruginosa, and the levels of other amino acids
are also affected by this mechanism.21 Therefore, the levels of
leucine or isoleucine together with other amino acids detected
in this study may be confounded by the distribution of P.
aeruginosa infection in patients. Butyric acid has been found to
be secreted by anaerobic bacteria found in CF airways, and it
was also detected in bronchoalveolar lavage fluid samples from
CF patients.22 In this study, both the mean and median levels
of butyric acid were higher in APE pediatric samples compared
to stable CF and pre-APE ones (Figure 2C). Butyric acid,
together with acetic acid and propionic acid, which also
appeared in the discriminant feature panels (Tables 1 and 2
and S5 and S6), are short-chain fatty acids associated with
immune and inflammatory processes in CF airways.22
Interestingly, acetic acid was identified as one of the potential
EBC biomarkers for discriminating stable CF patients from
unstable CF patients during exacerbations in a metabolomics
study using NMR.11
Interestingly, 4-hydroxycyclohexanecarboxylic acid, which is
a metabolite associated with gut microbial mammalian
cometabolism and one of the two discriminant features in
the model for APE versus stable CF sample classification in the
pilot study,12 appeared in multiple discriminant panels in this
larger cohort study (Tables 1 and 2 and S5 and S6). In
addition, pyroglutamic acid, which is involved in the γ-glutamyl
cycle and present in both APE versus stable CF and pre-APE
versus stable CF discriminant panels in the pilot study,12 also
appeared in the nine-feature negative mode data model
Figure 3. Pathway analysis of the 23 uniquely-identified discriminant metabolites from all panels, including EBC samples from APE vs stable CF
(A) pediatric and (B) adult patients, and pre-APE vs stable CF in (C) pediatric and (D) adult patients. Each circle on the map represents a
pathway, and the size and color of the circle are based on the p-value, indicating the significance of the changes in the matched metabolites in the
pathway, and the pathway impact score, which is correlated with the centrality of the metabolites involved.15,38
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differentiating APE from stable CF pediatric samples (Table
1). These metabolites, selected for discrimination in both
studies in a nonsupervised fashion, corroborated the biological
significance and implications for future diagnostic approaches
of the panels described here.
Malic acid, which was present in the 11-feature negative ion
mode oPLS-DA model for classification of pre-APE and stable
CF pediatric patient samples, was significantly decreased in
pre-APE, with a large median fold change of 2.0 × 102 (Table
2). Malic acid has been recently detected in exhaled breath for
the first time by secondary ESI high-resolution MS,23 and it
was reported to have cardioprotective effects possibly due to its
anti-inflammatory properties.24 In addition, it is involved in
pyruvate metabolism, which was found to be significantly
altered between APE and stable CF pediatric samples (Figure
3A). Free carnitine, which was identified in the adult APE
versus stable CF discriminant panel of the model using
combined negative and positive ion mode data had a 1.5 fold
increase in APE samples (Table S5). Carnitine can be either
synthesized in the human body or obtained from dietary red
meat and metabolized by intestinal bacteria.25 It is involved in
fatty acid transport to mitochondria, with abnormal fatty acid
metabolism having been postulated to be associated with
CF.25−28 Interestingly, free carnitine levels in plasma have been
reported to be significantly higher in CF patients compared to
healthy controls.29 To the best of our knowledge, carnitine has
not been previously detected in EBC. Formylanthranilic acid
and oxindole (Tables S5 and S6) are involved in tryptophan
metabolism,30 and tryptophan was also selected as a
discriminant compound in the classification model of APE
versus stable CF pediatric samples (Table S5). Tryptophan
metabolism plays a crucial role in gut mucosal homeostasis and
microbiome regulation,31 and it was found to be significantly
altered in primary human airway epithelial cells from CF
patients compared to those from non-CF individuals in a
metabolic profiling study by Wetmore et al.32 Further
investigation of the microbial metabolites and integration of
CF microbiome studies with metabolomics should improve
our current understanding of host−pathogen interactions in
APE development and progression, guiding clinical decisions
for early intervention and personalized APE treatment.33
Pathway analysis of the 23 uniquely identified discriminant
metabolites from all panels revealed pathways with significant
changes in APE and pre-APE compared to stable CF patients.
These included arginine and proline metabolism, which were
found to be significantly altered in pre-APE adult and pediatric
samples, and pyruvate metabolism, which was significantly
changed between APE and stable CF pediatric patients (Figure
3). Arginine was one of the 11 discriminant features
responsible for classification of adult pre-APE from stable CF
samples, with a 3.1-fold increase in the pre-APE group (Table
S6). Its concentration in EBC has been shown to be associated
with lung function, with a significant negative correlation with
percent predicted forced vital capacity and a nearly significant
negative correlation with percent predicted FEV1.
34 Proline
and glutamic acid, identified as discriminant metabolites
between pre-APE and stable CF pediatric patients, are
downstream products of arginase.35 In this binary comparison,
proline had a 2.4-fold decrease and glutamic acid had a 1.3-fold
increase in abundance in pre-APE pediatric patients (Table
S6). Significantly increased proline and glutamic acid levels
were found after antibiotic treatment of APE,35 suggesting that
further research is needed to elucidate the mechanisms
involved in the observed alterations of this metabolic pathway
during CF APE progression.
Pyruvate metabolism, including lactic acid and acetic acid,
was found to be altered in EBC samples collected from
pediatric patients during an APE compared to those from
stable CF pediatric patients. Malic acid was also identified as
being significantly altered in EBC samples collected from
pediatric patients in the 3-month time window before an APE
event. Pyruvate metabolism is at a key intersection of many
pathways in human biological systems including glycolysis and
the citric acid cycle, and abnormalities in pyruvate metabolism
have been strongly associated with various diseases.36 The flux
of pyruvate metabolism is highly diverse in different strains of
P. aeruginosa,37 and its relationship to CF also warrants further
investigation.
In conclusion, nontargeted EBC metabolic profiling
combined with supervised multivariate classification models
demonstrated good performance for detecting APEs and
predicting an oncoming APE event. EBC metabolites
exhibiting significant changes at different stages of an APE
event were discussed in relation to the altered metabolic
pathways and their microbial relevance. All three discriminant
metabolites in the pilot study were also selected in this larger
cohort in a nonsupervised fashion, validating the biological
significance of the panels identified for APE detection and
prediction. One limitation of the study, however, is the lack of
sufficient number of longitudinal EBC samples collected from
the same patient at different stages of APE progression for time
series analysis. In addition, further investigation of the CF
microbiome should aid to improve our current understanding
of the link between host and pathogen interactions in APE
development and progression and to obtain chemical
information on pathogen-specific metabolites that may assist
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